Developer docs
API playgroundTry for free, no card

Search company profiles

Mamedica

Full company profile

uuid0000j9q

Namestring
Mamedica
Legal namestring
Mamedica Limited
Websiteurl
mamedica.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Mamedica, operating as Mamedica Limited, is a UK-based private medical cannabis clinic headquartered in London that prescribes cannabis-based medicines to patients suffering from chronic conditions including chronic pain, anxiety, depression, ADHD, PTSD, fibromyalgia, arthritis, insomnia, and back/neck pain. The company operates a direct-to-consumer digital healthcare platform centred on a patient-facing app (app.mamedica.com) where prospective patients complete an eligibility checker, book consultations with specialist doctors, and manage repeat prescriptions. It dispenses five product formats — dried flower, oils, vapes, pastilles, and capsules — through the separate Mamedica Dispensary e-commerce platform, with medication delivered directly to patients' homes and reported 24-hour fulfilment times.

The business model is built around recurring subscription revenue across four pricing tiers: Flex (£49 onboarding plus follow-up fees), Standard (£150/month with one free delivery and no clinic fees after 9 months), Access (£200/month with zero clinic fees for life for students, veterans, and benefit claimants), and Transfer (£75 for patients switching from other clinics). The company is CQC-registered (rated Good in November 2024) and operates from a single UK headquarters at 20 Midtown, London. As of 2025 it serves 15,000+ patients, is recognised in The Sunday Times 100 2026 as the UK's #8 fastest-growing private company, and employs 51-100 staff. It received £4.5 million in growth funding from US-based cannabis-focused VC Casa Verde in September 2025 to support platform improvements, patient base doubling, and European expansion.

Short descriptiontext

Mamedica is a UK-based, CQC-registered medical cannabis clinic that uses a digital patient platform to prescribe cannabis-based medicines for chronic conditions such as chronic pain, anxiety, and PTSD, serving 15,000+ patients via direct-to-door delivery and subscription plans.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis prescriptions, cannabis-based medications, chronic pain treatment, digital healthcare platform, specialist doctor consultations
Industry3 codes
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAF
Cannabis Dispensary with On-Site Consumption Lounge (where permitted)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Offices of Physicians62111
  • Outpatient Mental Health and Substance Abuse Centers621420
SIC code2 codes
  • Services-Health Services8000
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Medical Cannabis Clinic
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Consultation Fees
TypeSubscription Recurring
Description

Patients pay for initial consultations and follow-up appointments with specialist doctors. The Standard plan includes one free delivery per month.

mamedica.co.uk
2Treatment Plans
TypeSubscription Recurring
Description

Ongoing revenue from prescribed cannabis-based medications delivered to patients monthly. Patients pay clinic fees for ongoing care, with no clinic fees after 9 months.

mamedica.co.uk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D
Pricing details4 tiers
1Lower monthly fees with flexibility for ongoing care patients
ModelSubscriptionBilling cadenceMonthly
Notes

£49 one-time onboarding fee plus follow-up consultation fees

mamedica.co.uk
2Best value long-term plan with one free delivery every month
ModelSubscriptionBilling cadenceMonthly
Notes

£150

mamedica.co.uk
3Zero clinic fees for students, veterans, and benefit claimants
ModelSubscriptionBilling cadenceMonthly
Notes

£200 with zero clinic fees for life. Restrictions apply.

mamedica.co.uk
4Transfer pricing for patients switching from other clinics
ModelSubscriptionBilling cadenceOne time/ perpetual license
Notes

£75 transfer fee

mamedica.co.uk
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Mamedica is a UK-based CQC-registered medical cannabis clinic that prescribes cannabis-based medications (flower, oils, vapes, pastilles, capsules) through specialist doctor consultations for chronic conditions such as chronic pain, anxiety, depression, ADHD, PTSD, fibromyalgia, arthritis, insomnia, and back/neck pain. Patients access care via an online eligibility checker and digital patient portal, with prescribed medication delivered directly to their door.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 15,000+ patients served
+2 more records
Product overview1 text field

Mamedica is a UK medical cannabis clinic offering a platform-based model combining digital healthcare services with cannabis-based medication products. The core offering includes specialist doctor consultations and a digital patient portal (app.mamedica.com) for eligibility checking, prescriptions, and ongoing treatment management. The company prescribes five distinct cannabis-based product forms: Flower (dried cannabis for vaporisation), Oils (cannabis extracts in oil form), Vapes (vapour delivery products), Pastilles (edible pastilles), and Capsules (gel capsules). These medications are delivered directly to patients via the Mamedica Dispensary. Pricing is structured across four subscription tiers: Flex (flexible payments), Standard (best value with free delivery), Access (zero clinic fees for students, veterans, and benefit claimants), and Transfer (for patients switching clinics).

Product and service8 records
1Medical Cannabis Consultation Services
CategoryHealthcare Services
Description

Specialist doctor consultations to assess patient eligibility and prescribe cannabis-based medicines for conditions including anxiety, chronic pain, insomnia, and other chronic conditions.

2Flower (Dried Cannabis)
CategoryCannabis-based Medication
Description

Dried cannabis flower for vaporisation, offering fast symptom relief for medical cannabis patients.

3Cannabis Oils
CategoryCannabis-based Medication
Description

Cannabis extracts in oil form, ideal for precise, measured dosing for daily symptom management.

4Cannabis Vapes
CategoryCannabis-based Medication
Description

Discreet, fast-acting vapour delivery using high-quality cannabis extracts.

5Cannabis Pastilles
CategoryCannabis-based Medication
Description

Flavoured, dose-controlled edible cannabis products designed for daily relief.

6Cannabis Capsules
CategoryCannabis-based Medication
Description

Odourless, dose-controlled gel capsules designed for daily relief.

7Patient Portal
CategoryDigital Healthcare Platform
Description

Digital healthcare platform enabling patient login, eligibility checking, repeat prescriptions, and treatment management accessible via app.mamedica.com.

8Mamedica Dispensary
CategoryDispensary E-commerce
Description

Online dispensary for dispensing prescribed medical cannabis products to patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based medical cannabis clinic with a digital-first patient onboarding and prescribing model targeting chronic conditions. Direct peer competing in the same online eligibility and consultation funnel.

TypeEmerging player
Description

UK-listed pharmaceutical company developing cannabis-based medicines, with related medicinal-cannabis operations. Comparable category exposure though positioned upstream as a supplier rather than prescriber.

TypeDirect peer
Description

UK-based medical cannabis clinic providing specialist doctor consultations and prescriptions across chronic pain, mental health, and other conditions. Direct peer offering the same regulated clinic + delivery model.

4Emmac Life Sciences / Curaleaf International (parent)
TypeBroad incumbent
Description

European medical cannabis operator with cultivation, distribution, and clinic assets including UK clinics. Comparable as a broader incumbent across the medical cannabis value chain.

TypeDirect peer
Description

UK medical cannabis clinic providing specialist consultations and prescriptions for chronic pain, mental health, and other qualifying conditions. Direct peer operating under the same CQC regulatory framework.

6Zerenia Clinic (formerly The Beeches Clinic)
TypeDirect peer
Description

UK clinic offering specialist medical cannabis consultations and prescriptions for chronic conditions. Direct peer with CQC-registered prescribers and subscription-style clinic fees.

TypeDirect peer
Description

UK clinic network offering specialist doctor consultations and medical cannabis prescriptions. Direct peer with overlapping patient indications and prescriber-led delivery model.

8Zana Medical
TypeEmerging player
Description

Smaller UK medical cannabis clinic providing specialist consultations and prescriptions. Emerging peer with partial overlap in chronic condition indications and digital onboarding.

TypeDirect peer
Description

One of the largest UK medical cannabis clinic operators, with multiple specialist clinics across the UK offering similar doctor-led cannabis prescriptions for chronic conditions. Direct competitor in the same CQC-regulated clinical model.

TypeDirect peer
Description

UK medical cannabis clinic operated by Curaleaf International, providing specialist consultations and cannabis prescriptions. Direct peer with overlapping prescriber base and product range.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mamedica

Medical Cannabis Clinicmamedica.com

Mamedica is a UK-based, CQC-registered medical cannabis clinic that uses a digital patient platform to prescribe cannabis-based medicines for chronic conditions such as chronic pain, anxiety, and PTSD, serving 15,000+ patients via direct-to-door delivery and subscription plans.

What Mamedica does

Mamedica, operating as Mamedica Limited, is a UK-based private medical cannabis clinic headquartered in London that prescribes cannabis-based medicines to patients suffering from chronic conditions including chronic pain, anxiety, depression, ADHD, PTSD, fibromyalgia, arthritis, insomnia, and back/neck pain. The company operates a direct-to-consumer digital healthcare platform centred on a patient-facing app (app.mamedica.com) where prospective patients complete an eligibility checker, book consultations with specialist doctors, and manage repeat prescriptions. It dispenses five product formats — dried flower, oils, vapes, pastilles, and capsules — through the separate Mamedica Dispensary e-commerce platform, with medication delivered directly to patients' homes and reported 24-hour fulfilment times.

The business model is built around recurring subscription revenue across four pricing tiers: Flex (£49 onboarding plus follow-up fees), Standard (£150/month with one free delivery and no clinic fees after 9 months), Access (£200/month with zero clinic fees for life for students, veterans, and benefit claimants), and Transfer (£75 for patients switching from other clinics). The company is CQC-registered (rated Good in November 2024) and operates from a single UK headquarters at 20 Midtown, London. As of 2025 it serves 15,000+ patients, is recognised in The Sunday Times 100 2026 as the UK's #8 fastest-growing private company, and employs 51-100 staff. It received £4.5 million in growth funding from US-based cannabis-focused VC Casa Verde in September 2025 to support platform improvements, patient base doubling, and European expansion.

Mamedica firmographics

Firmographics
Name
Mamedica
Legal name
Mamedica Limited
Website
https://mamedica.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Mamedica is a UK-based, CQC-registered medical cannabis clinic that uses a digital patient platform to prescribe cannabis-based medicines for chronic conditions such as chronic pain, anxiety, and PTSD, serving 15,000+ patients via direct-to-door delivery and subscription plans.
Ownership category
akta.pro rank

Mamedica industry classification

Industry
Product category
Medical Cannabis Clinic
NAICS
Offices of Physicians (62111), Outpatient Mental Health and Substance Abuse Centers (621420)
SIC
Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAF
Cannabis Dispensary with On-Site Consumption Lounge (where permitted)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medical cannabis prescriptions
  • Cannabis-based medications
  • Chronic pain treatment
  • Digital healthcare platform
  • Specialist doctor consultations

Where Mamedica is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Mamedica business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

  1. Consultation Fees: Patients pay for initial consultations and follow-up appointments with specialist doctors. The Standard plan includes one free delivery per month.
  2. Treatment Plans: Ongoing revenue from prescribed cannabis-based medications delivered to patients monthly. Patients pay clinic fees for ongoing care, with no clinic fees after 9 months.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyLower monthly fees with flexibility for ongoing care patients
SubscriptionMonthlyBest value long-term plan with one free delivery every month
SubscriptionMonthlyZero clinic fees for students, veterans, and benefit claimants
SubscriptionOne time/ perpetual licenseTransfer pricing for patients switching from other clinics

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Mamedica product offering

Product offering

Core offering

Mamedica is a UK-based CQC-registered medical cannabis clinic that prescribes cannabis-based medications (flower, oils, vapes, pastilles, capsules) through specialist doctor consultations for chronic conditions such as chronic pain, anxiety, depression, ADHD, PTSD, fibromyalgia, arthritis, insomnia, and back/neck pain. Patients access care via an online eligibility checker and digital patient portal, with prescribed medication delivered directly to their door.

Product overview

Mamedica is a UK medical cannabis clinic offering a platform-based model combining digital healthcare services with cannabis-based medication products. The core offering includes specialist doctor consultations and a digital patient portal (app.mamedica.com) for eligibility checking, prescriptions, and ongoing treatment management. The company prescribes five distinct cannabis-based product forms: Flower (dried cannabis for vaporisation), Oils (cannabis extracts in oil form), Vapes (vapour delivery products), Pastilles (edible pastilles), and Capsules (gel capsules). These medications are delivered directly to patients via the Mamedica Dispensary. Pricing is structured across four subscription tiers: Flex (flexible payments), Standard (best value with free delivery), Access (zero clinic fees for students, veterans, and benefit claimants), and Transfer (for patients switching clinics).

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical Cannabis Consultation Services Specialist doctor consultations to assess patient eligibility and prescribe cannabis-based medicines for conditions including anxiety, chronic pain, insomnia, and other chronic conditions.
  • Flower (Dried Cannabis) Dried cannabis flower for vaporisation, offering fast symptom relief for medical cannabis patients.
  • Cannabis Oils Cannabis extracts in oil form, ideal for precise, measured dosing for daily symptom management.
  • Cannabis Vapes Discreet, fast-acting vapour delivery using high-quality cannabis extracts.
  • Cannabis Pastilles Flavoured, dose-controlled edible cannabis products designed for daily relief.
  • Cannabis Capsules Odourless, dose-controlled gel capsules designed for daily relief.
  • Patient Portal Digital healthcare platform enabling patient login, eligibility checking, repeat prescriptions, and treatment management accessible via app.mamedica.com.
  • Mamedica Dispensary Online dispensary for dispensing prescribed medical cannabis products to patients.

Quantifiable outcome

  • 15,000+ patients served
  • +2 more outcomes

Companies that use Mamedica

Customer profile

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Mamedica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature3 records

Mamedica partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Mamedica competitors and assessment

Company assessment

Direct peers

  • Alternaleaf: UK-based medical cannabis clinic with a digital-first patient onboarding and prescribing model targeting chronic conditions. Direct peer competing in the same online eligibility and consultation funnel.
  • Sapphire Medical Clinics: UK-based medical cannabis clinic providing specialist doctor consultations and prescriptions across chronic pain, mental health, and other conditions. Direct peer offering the same regulated clinic + delivery model.
  • CB1 Medical: UK medical cannabis clinic providing specialist consultations and prescriptions for chronic pain, mental health, and other qualifying conditions. Direct peer operating under the same CQC regulatory framework.
  • Zerenia Clinic (formerly The Beeches Clinic): UK clinic offering specialist medical cannabis consultations and prescriptions for chronic conditions. Direct peer with CQC-registered prescribers and subscription-style clinic fees.
  • Cannabis Access Clinics (Dr. David McDowell): UK clinic network offering specialist doctor consultations and medical cannabis prescriptions. Direct peer with overlapping patient indications and prescriber-led delivery model.
  • LYPHE Group (formerly The Medical Cannabis Clinics): One of the largest UK medical cannabis clinic operators, with multiple specialist clinics across the UK offering similar doctor-led cannabis prescriptions for chronic conditions. Direct competitor in the same CQC-regulated clinical model.
  • Curaleaf Clinic (formerly LYPHE Clinic): UK medical cannabis clinic operated by Curaleaf International, providing specialist consultations and cannabis prescriptions. Direct peer with overlapping prescriber base and product range.

Emerging players

  • Celadon Pharmaceuticals: UK-listed pharmaceutical company developing cannabis-based medicines, with related medicinal-cannabis operations. Comparable category exposure though positioned upstream as a supplier rather than prescriber.
  • Zana Medical: Smaller UK medical cannabis clinic providing specialist consultations and prescriptions. Emerging peer with partial overlap in chronic condition indications and digital onboarding.

Broad incumbents

  • Emmac Life Sciences / Curaleaf International (parent): European medical cannabis operator with cultivation, distribution, and clinic assets including UK clinics. Comparable as a broader incumbent across the medical cannabis value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Mamedica social profiles

Digital presence

Mamedica compliance and trust

Trust signal

Compliance1 record

Mamedica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mamedica leadership team

Management profile

Number of profiles

Profiles1 record

Mamedica funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mamedica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mamedica

What does Mamedica do?

Mamedica is a UK-based CQC-registered medical cannabis clinic that prescribes cannabis-based medications (flower, oils, vapes, pastilles, capsules) through specialist doctor consultations for chronic conditions such as chronic pain, anxiety, depression, ADHD, PTSD, fibromyalgia, arthritis, insomnia, and back/neck pain. Patients access care via an online eligibility checker and digital patient portal, with prescribed medication delivered directly to their door.

Is Mamedica a public or private company?

Mamedica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mamedica founded?

Mamedica was founded in 2021. It employs 51 to 100 people.

Where is Mamedica based?

Mamedica is headquartered in London, United Kingdom, in the Europe region.

How does Mamedica make money?

Two revenue lines are on record. Consultation Fees are the primary driver. The others are treatment Plans.

Who are Mamedica's main competitors?

Direct peers on record are Alternaleaf, Sapphire Medical Clinics, CB1 Medical, Zerenia Clinic (formerly The Beeches Clinic), Cannabis Access Clinics (Dr. David McDowell), LYPHE Group (formerly The Medical Cannabis Clinics) and Curaleaf Clinic (formerly LYPHE Clinic). Emerging players are Celadon Pharmaceuticals and Zana Medical. Emmac Life Sciences / Curaleaf International (parent) is listed as a broad incumbent.

Does Mamedica have an API?

No public API is recorded for Mamedica.

What industry is Mamedica in?

Mamedica's product category is Medical Cannabis Clinic. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAG, Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail). Its NAICS code is 62111 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooExclusive: Blade Brown Moves Into Medical Cannabis As Mamedica InvestorBlade Brown joined Mamedica as an investor and partner in the UK medical cannabis sector. Mamedica secured £4.5 million in funding in September 2025, with annualised sales of £21.5 million and a patient base exceeding 15,000.TechRoundHow Can We Support The Healthtech Boom Without Widening Global Healthcare Inequality?Healthcare technology advances rapidly, but risks widening global inequality if only wealthy systems benefit. Experts argue solutions must be designed for underserved communities, citing a Stanford study where over 80% of AI chatbot users came from communities of color. Governments and investors must prioritize accessibility and trust.PR NewswireMEDICAL CANNABIS CONSORTIUM LAUNCHES FIRST MULTI-CLINIC PATIENT SURVEY OF ITS KINDA multi-clinic survey of 6,282 UK patients prescribed medical cannabis for anxiety, depression, or PTSD found 97.6% reported symptom improvement and 88.3% rated it the most effective treatment. The consortium plans to repeat the survey annually and support further research into treatment-resistant mental health conditions.FinSMEsMamedica Raises £4.5M in FundingMamedica, a UK-based cannabis-based prescription medicine provider, raised £4.5M in funding led by Casa Verde. The company will use the funds to expand operations and R&D. It has treated over 10,000 patients since its 2022 launch.YahooMamedica, the UK's leading medical cannabis clinic, announces £4.5M funding round led by US-based Casa VerdeMamedica, the UK's leading medical cannabis clinic, announced a £4.5 million funding round led by Casa Verde. The capital will scale operations, expand clinical networks, and advance its digital platform. The company has treated over 10,000 patients and expects to double patient numbers annually as the UK market approaches £1bn in annual sales by 2028.citybizMamedica Raises £4.5M Funding Round Led by US-based Casa VerdeMamedica, the UK's leading medical cannabis provider, has secured a £4.5 million funding round led by US-based cannabis venture capital firm Casa Verde. The capital will be used to scale operations through supply chain optimization, expand clinical network access, and advance its proprietary digital healthcare platform. The company has grown significantly, achieving 1,250% patient growth in 2023 and 154% growth in 2024, and projects the UK medical cannabis market will reach £1 billion in annual sales by the end of 2028.PR NewswireMamedica, the UK's leading medical cannabis clinic, announces £4.5M funding round led by US-based Casa VerdeMamedica, the UK's leading medical cannabis clinic, announced a £4.5 million funding round led by US-based venture capital firm Casa Verde. The capital will be used to scale operations, expand the clinical network, advance its digital healthcare platform, and drive education around medical cannabis integration into mainstream healthcare. The UK medical cannabis market is approaching £1bn in annual sales by the end of 2028, with Mamedica expecting to double patient numbers annually while currently serving approximately 7,500 active patients.BBCMedical cannabis: London clinics see rise in patientsPrivate medical cannabis clinics in London are seeing a rise in patients, with Mamedica reporting a 10-fold increase from 250 to 2,750 in 2023. The NHS has prescribed fewer than five patients, citing a lack of evidence, while campaigners call for wider access and subsidies.